# US 2026/0263638 A1 · Compositions and methods to improve rna properties using base, phosphodiester linkage, sugar backbone, and cap modifications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263638 A1
- Document ID: US20260263638A1
- Status: Published application
- Kind: A1
- Application number: 19/545,537
- Filed: 2026-02-20
- Published: 2026-09-10
- Earliest claimed: 2023-08-23
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology
- Applicants: The Broad Institute, Inc.; Massachusetts Institute of Technology
- Inventors: Xiao Wang; Hongyu Chen; Dangliang Liu
- Web page: https://patentgrep.com/patent/US20260263638A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are capped RNA transcripts comprising one or more modified nucleotides at position +3 or higher with reference to a 5′ terminus of the RNA molecule, and methods of making the same. Also provided are compositions comprising one or more of the capped RNA transcripts provided herein, and methods of using said compositions for therapeutic applications.

## Claims

### Claim 1

A method of producing a composition of capped RNA transcripts, comprising:
(a) synthesizing a 5′-phosphorylated RNA oligonucleotide in a solvent system comprising a nonpolar counterion;
(b) capping the 5′-phosphorylated RNA oligonucleotide, thereby producing a capped RNA oligonucleotide;
(c) purifying the capped RNA oligonucleotide, thereby producing a composition comprising a purified capped RNA oligonucleotide, wherein at least 95% of the total RNA oligonucleotides in the composition are capped RNA oligonucleotides; and
(d) ligating the purified capped RNA oligonucleotide to an RNA precursor, thereby producing a capped RNA transcript.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the capping is performed through an anhydrous reaction between the 5′-phosphorylated RNA oligonucleotide and a capping nucleotide conjugated to imidazole in the presence of 1-methylimidazole.

### Claim 7 (depends on 1)

The method of claim 1, wherein the RNA precursor comprises one or more of a 5′ untranslated region (5′ UTR) comprising an unstructured region, a 3′ exonuclease-resistant modification, a poly-A tail, an open reading frame (ORF), and a therapeutic nucleic acid.

### Claim at position 5

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein at least 95% of the capped RNA transcripts produced in step (d) comprise a 5′ cap.

### Claim at position 7

-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, further comprising circularizing the capped RNA transcript.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, further comprising:
(i) introducing one or more azide handles onto the 5′-phosphorylated RNA oligonucleotide, and
(ii) conjugating one or more 5′ cap regions to the 5′-phosphorylated RNA oligonucleotide via click chemistry with the one or more azide handles.

### Claim at position 11

-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein at least one of the 5′-phosphorylated RNA oligonucleotide and the RNA precursor comprises one or more modified nucleotides, wherein the one or more modified nucleotides comprise one or more modified sugars, one or more modified phosphates, one or more modified nucleobases, or any combination thereof.

### Claim at position 13

-46. (canceled)

### Claim 47 (depends on 1)

The method of claim 1, wherein the capped RNA oligonucleotide comprises a 5′ cap selected from the group consisting of 7-methyguanosine (m7G), N7,3′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine (m7G-3′m-ppp-G), N7,2′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine (m7Gm-ppp-G), 7-benzylguanosine (Bn7G), chlorobenzylguanosine (ClBn7G), m7G bearing an LNA sugar (m7G-LNA), chlorobenzyl-O-ethoxyguanosine (ClBnOEt7G), 7-(4-chlorophenoxyethyl)-guanosine, 7-ethyl guanosine (e7G), 7-propyl guanosine (p7G), 7-isopropyl guanosine (ip7G), 7-butyl guanosine (b7G), 7-isobutyl guanosine (ib7G), 7-cyclopentyl guanosine (cp7G), 7-(carboxymethyl) guanosine (cm7G), 7-(2-phenylethyl) guanosine [7-(2-PhEt)G], 7-(1-phenylethyl) guanosine [7-(1-PhEt)G], m7GpppBH3G (D1 and D2 stereoisomers), m7GppBH3G (D1 and D2 stereoisomers), m7GpBH3G (D1 and D2 stereoisomers), m7GppBH3pm7G, m27,2′-OGpppBH3G (D1 and D2 stereoisomers), m27,2′-OGppBH3PG (D1 and D2 diastereomers), m27,2′-OGppspG (D1 and D2 diastereomers), N-Arylmethyl analogs, glyceryl, 4′,5′-methylene nucleotide, 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide, carbocyclic nucleotide, 1,5-anhydrohexitol nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3′,4′-seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5-dihydroxypentyl nucleotide, 3′-3 ‘-inverted nucleotide moiety, 3’-3′-inverted abasic moiety, 3′-2′-inverted nucleotide moiety, 3′-2 ‘-inverted abasic moiety, 1,4-butanediol phosphate, 3’-phosphoramidate, hexylphosphate, aminohexyl phosphate, 3′-phosphate, 3′-phosphorothioate, phosphorodithioate, cap1, cap2, cap3, cap4, ARCA, modified ARCA, inosine, N1-methylguanosine, LNA-guanosine, 2-azido-guanosine, and a bridging or non-bridging methylphosphonate moiety.

### Claim at position 15

-66. (canceled)

### Claim 67 (depends on 1)

A capped RNA transcript produced by the method of claim 1.

### Claim at position 17

-71. (canceled)

### Claim 72 (depends on 67)

A composition comprising the capped RNA transcript of claim 67.

### Claim at position 19

-78. (canceled)

### Claim 79 (depends on 67)

A method of preventing or treating a disease in a subject, comprising introducing an effective amount of the capped RNA transcript of claim 67 to the subject.

### Claim at position 21

-84. (canceled)

### Claim 85

A method of screening for altered translation efficiency or RNA stability conferred by one or more nucleotide modifications in an RNA transcript, comprising:
(a) synthesizing a 5′-phosphorylated RNA oligonucleotide comprising one or more modified nucleotides in a solvent system comprising a nonpolar counterion;
(b) chemically capping the 5′-phosphorylated RNA oligonucleotide, thereby producing a capped RNA oligonucleotide;
(c) purifying the capped RNA oligonucleotide;
(d) ligating the capped RNA oligonucleotide to an RNA precursor comprising an open reading frame (ORF) encoding a protein, thereby producing a capped RNA transcript;
(e) expressing the capped RNA transcript in a cell; and
(f) measuring expression of the protein in the cell.

### Claim at position 23

-166. (canceled)

### Claim 167

An RNA molecule comprising (i) one or more modified nucleotides at position +3 or higher with reference to a 5′ terminus of the RNA molecule, and (ii) at least one 5′ cap.

### Claim 168 (depends on 167)

The RNA molecule of claim 167 comprising two or more 5′ caps, wherein the two or more 5′ caps are conjugated to the RNA molecule via click chemistry or a photochemical crosslinking reaction.

### Claim at position 26

-200. (canceled)

### Claim 201 (depends on 167)

The RNA molecule of claim 167, further comprising one or more of an open reading frame (ORF), one or more poly-A tails, and a therapeutic nucleic acid.

### Claim at position 28

-208. (canceled)

### Claim 209 (depends on 167)

A vector comprising the RNA molecule of claim 167.

### Claim 210 (depends on 167)

A delivery agent comprising the RNA molecule of claim 167, wherein the delivery agent comprises a lipid, a peptide, a protein, an antibody, a carbohydrate, a nanoparticle, or a microparticle.

### Claim at position 31

-213. (canceled)

### Claim 214 (depends on 167)

A composition comprising the RNA molecule of claim 167.

### Claim at position 33

-220. (canceled)

### Claim 221 (depends on 167)

A method of preventing or treating a disease in a subject, comprising introducing an effective amount of the RNA molecule of claim 167 to the subject.

### Claim at position 35

-224. (canceled)

### Claim 225 (depends on 220)

A kit comprising the composition of claim 220, a device for administering the composition to a subject, and/or instructions for administering the composition to the subject.
